PureTech names Nobel Laureate among new members of scientific advisory board
pharmafile | December 1, 2015 | Appointment | Medical Communications, Research and Development | PureTech Health, puretech
PureTech Health has compiled a scientific advisory board of distinguished scientists and physicians to expand its senior team.
The scientific advisory board will work closely with PureTech’s board and executive team to identify new areas of focus and to prioritize themes and new company concepts.
The board is chaired by H. Robert Horvitz (pictured), who is PureTech board advisor, Nobel Laureate and David H. Koch professor at the Massachusetts Institute of Technology (MIT).
Its initial members include Dennis Ausiello, chief emeritus of medicine at Massachusetts General Hospital, James Collins, professor of biological engineering at MIT, Sanjiv Sam Gambhir, Ludwig professor at Stanford University, Raju Kucherlapati, PureTech board member, Paul Cabot, professor of genetics and professor of medicine at Harvard Medical School, and PureTech co-founder Robert Langer.
Additionally, PureTech named Harry Leider, chief medical officer of Walgreens, as a senior advisor to the company. PureTech is also expanding its senior team with the addition of Joseph Bolen, who has been appointed ‘entrepreneur-in-residence’. Dr Bolen is the former president of research and development at Moderna Therapeutics and former chief scientific officer at Millennium Pharmaceuticals. Additionally, the Company appointed Vincent Hennemand, former principal in Sanofi’s corporate R&D venture group, as vice president of development and operations.
Daphne Zohar, who is chief executive of PureTech says: “The scientific advisory board members, all leaders in their respective fields, share PureTech’s vision of addressing major healthcare problems in unexpected ways. They will work closely with PureTech’s world-class scientific and clinical advisory network and our team. We are excited to welcome our new advisors and senior team members.”
Related Content
PureTech Health launches Seaport Therapeutics
PureTech Health has announced key progress on its ‘strategic initiatives to deliver innovative medicines to …
PureTech Health’s Founded Entity Akili announces positive data from adult ADHD trial
Clinical-stage biotherapeutics company PureTech Health has reported that its Founded Entity Akili, a digital medicine …
Digital software shows benefit in ADHD trial
A pilot study of a digital health technology designed to improve symptoms of attention deficit …
